previous arrow
next arrow
Slider

Issued on behalf of Premaitha Health plc
Manchester, UK: Monday, 12 October 2015

Independent performance study of the IONA® test published

Further verification of the test showing 100% of trisomies detected and 0% false positives from 242 maternal blood samples

Manchester, UK – 12 October 2015 – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT), developer of the IONA® test, the first CE-marked non-invasive prenatal screening test (NIPT), announces the results of a study on the first-trimester detection of trisomy 21, 18 and 13 using the IONA® test1. The study was undertaken by a team led by Professor Kypros Nicolaides with Dr Liona Poon as the lead author at the Harris Birthright Research Centre for Fetal Medicine, King’s College Hospital, London, and was published in the Journal of Ultrasound in Obstetrics and Gynaecology.

The blinded validation study, assessed the potential performance of the IONA® test in using cell-free DNA analysis of 242 maternal blood samples to screen for Down’s syndrome (Trisomy 21), Edwards’ syndrome (Trisomy 18) and Patau’s syndrome (Trisomy 13). Samples were obtained from pregnant women at 11 to 13 weeks gestation before chorionic villus sampling. The maternal plasma samples were then analysed in Premaitha’s laboratories using the IONA® test.

The test results were analysed using the IONA® Software, Premaitha’s bespoke bioinformatics package available for all clinical laboratory customers. The IONA® test measures the relative amount of chromosomes 21, 18 and 13 in the maternal plasma sample to calculate a likelihood ratio to predict the presence of a trisomy. This data is coupled with the background risk associated with maternal age to determine an adjusted probability of the fetus having a trisomy of chromosome 21, 18 or 13. Of the 242 samples; 35 were trisomy 21, 4 were trisomy 18, and 2 were trisomy 13. The IONA® test detected 100% of all trisomies with a false positive rate of 0%.

Prof Kypros Nicolaides commented on the study “I am very impressed by the accuracy of the IONA® test” and Dr Liona Poon, both at the Harris Birthright Research Centre for Fetal Medicine, Division of Women's Health, King's College London said: “I hope the new technology used in the IONA® test will allow easy implementation of cfDNA testing in the screening for major fetal aneuploidies.”

Dr William Denman, Chief Medical Officer at Premaitha said: “These results confirm what our customers have already reported; that the IONA® test is a highly accurate, robust and simple screen for Down’s syndrome and other serious genetic conditions. It is a great endorsement of the test that Professor Nicolaides and his team have chosen to validate it. We believe this should encourage broader and appropriate uptake of NIPT, benefiting pregnant women and their families through the increased accuracy, especially the reduction in false positive results that the IONA® test provides.”

NIPT is more sensitive and specific than the currently available combined test. NIPT provides pregnant women and their families a more accurate and reliable screening result, reducing the incidence of unnecessary and stressful invasive procedures like amniocentesis, and the associated risk of miscarriage.

-Ends-

Premaitha are exhibiting at the 25th World Congress on Ultrasound in Obstetrics and Gynecology, please visit us at booth 102.

1Ultrasound Obstet Gynecol. 2015 Sep 21. doi: 10.1002/uog.15749. The IONA® test for first-trimester detection of trisomy 21, 18 and 13. Poon LC1, Dumidrascu-Diris D1, Francisco C1, Fantasia I1, Nicolaides KH1.

For more information, please contact:

Premaitha Health plc
Dr Stephen Little, Chief Executive Officer
Jo Cross, Head of Marketing     

Tel: +44 (0) 161 667 6865
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.      
         This email address is being protected from spambots. You need JavaScript enabled to view it.

Instinctif Partners
Melanie Toyne Sewell / Jen Lewis / Emma Barlow    

Tel: +44 (0) 207 457  2020
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Cairn Financial Advisers LLP (NOMAD - Premaitha)
Liam Murray / Avi Robinson

Tel: +44 (0) 20 7148 7900
    
Panmure Gordon (UK) Limited (Broker - Premaitha)
Robert Naylor / Freddy Crossley / Maisie Rose Atkinson

Tel: +44 (0) 20 7886 2500

About Premaitha Health

Premaitha is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.  

The IONA® test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases. The IONA® test has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress.

The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their own facilities. This supports Premaitha’s strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.  

Premaitha is listed on the London Stock Exchange (AIM). Its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK.

For further information please visit www.premaitha.com or email This email address is being protected from spambots. You need JavaScript enabled to view it.   


About Harris Birthright Research Centre for Fetal Medicine

The Harris Birthright Research Centre for Fetal Medicine was set up in 1984 through the generosity of Sir Philip Harris and the charity organisation Birthright. It has developed into a major research and clinical unit for fetal diagnosis and therapy. Each year more than 10,000 patients benefit from its services and up to 100 doctors, midwives and scientists visit to observe its clinical activities and to participate in research. More than 400 papers have been published in scientific journals.

For further information please visit www.harrisbirthright.org

  • 16 August 2019 - Directorate Change Appointment of business development sector specialist as Non-executive Director +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Directorate Change

    Appointment of business development sector specialist as Non-executive Director 

    Manchester, UK – 16 August 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the appointment of Jonathan Seaton to the Board of Directors as a Non-executive Director, with immediate effect .

    Jonathan has extensive experience working for leading global life sciences and diagnostic companies having worked on more than 40 M&A transactions as well as strategic

    Read More
  • 29 July 2019 - Appointment of Director +

    Yourgene Health plc

    (“ Yourgene ”, the “ Company ” or the “ Group ”)

    Appointment of Director

    Manchester, UK – 29 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces the appointment of Dr John Brown CBE to the Board of Directors as a Non-executive Director with immediate effect.   Dr Brown will act as the Senior Independent Director on the Board.

    Dr Brown

    Read More
  • 10 July 2019 - Results for the Year Ended 31 March 2019, 
Business Update and Director Change +

    Yourgene Health plc

    (“ Yourgene ” or the “ Company ” or the “ Group ”)

    Results for the Year Ended 31 March 2019,
    Business Update and Director Change

      Manchester, UK – 10 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its results for the year ended 31 March 2019, and provides a business update.

    Full year results summary :

    • Comprehensive profit of

    Read More
  • 24 June 2019 - Yourgene participates in key global conferences +

    Yourgene Health plc
    (“Yourgene Health” or the "Company")

    Yourgene participates in key global conferences

    Manchester, UK - 24 June 2019: Yourgene Health (AIM : YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its participation at key conferences to raise the profile of its reproductive health products and services.

    European Society Human Genetics

    Yourgene recently attended the European Human Genetics Conference, organised by the European Society of Human Genetics. The event – held

    Read More
  • 25 April 2019 - Completion of Acquisition +

    THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS DOCUMENT.

    Yourgene Health plc
    (“Yourgene” or the “Company”)

    Read More
  • 17 April 2019 - Proposed acquisition of Delta Diagnostics (UK) Limited +

    Yourgene Health plc
    (“Yourgene” or the “Company”)

    Proposed acquisition of Delta Diagnostics (UK) Limited ("Elucigene")
    and
    Proposed placing of a minimum of 92,682,928new Ordinary Shares
    and
    Proposed subscription for 4,878,048new Ordinary Shares

    Highlights

    ● Proposed acquisition of Elucigene, a leading molecular diagnostics manufacturer and developer, complementary to Yourgene’s current and planned product offering

    ●  Acquisition consideration of £9.2 million (comprising £6.3 million cash and £2.9 million equity), includes £0.4 million of net cash, representing an enterprise

    Read More
  • 8 April 2019 - Full-year Trading Update +

    Yourgene Health plc

    (“Yourgene”, the “Company” or the “Group”)

    Full-year Trading Update

    Manchester, UK 8 April 2019 : Yourgene Health (AIM : YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a trading update for the year ended 31 March 2019.

    Trading Highlights

    ●  Unaudited revenues were ahead of market expectations, increasing by 45% to over £8.9m (2018: £6.1m), with growth in all active regions
    ●  Test volumes increased by 67% to

    Read More
  • 25 March 2019 - Yourgene raises IONA® test awareness in Egypt with British Ambassador (2) +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Yourgene raises IONA® test awareness in Egypt with British Ambassador

    Manchester, UK 25 March 2019 : Yourgene Health ( AIM : YGEN ) , the international molecular diagnostics group which commercialises genetic products and services, has held an event in Egypt to raise awareness of the IONA® test, a non-invasive prenatal DNA test for Down’s syndrome, amongst the clinical community.

    The event was attended by His Excellency Sir Geoffrey Adams, the British

    Read More
  • 18 February 2019 - Yourgene Health Announces Capital and Commercial Restructuring with Major Shareholder +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Yourgene Health Announces Capital and Commercial Restructuring

    with Major Shareholder

    Manchester, UK – 18 February 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a restructuring of its financial and commercial relationship with Life Technologies Limited (“Life Technologies”).

    Lyn Rees, CEO of Yourgene Health, commented:

    “I am delighted with the restructuring of our relationship with Life Technologies, which places Yourgene

    Read More
  • 8 January 2019 - High throughput NIPT solution for clinical laboratories +

    Yourgene Health plc
    (“Yourgene”, the “Company”)
     
    Yourgene launches Sage™ 32 plex
     
    High throughput NIPT solution for clinical laboratories
     
    Manchester, UK – 8 January 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, is pleased to announce the launch of the Sage™ 32 plex test, a new high throughput non-invasive prenatal testing (“NIPT”) and analysis solution for clinical laboratories. 
     
    Sage™ 32 plex uses the latest
    Read More
  • 3 December 2018 - Half-year Results +

    yourgene health logo RGB

    Yourgene Health plc
    (“Yourgene”, the “Company” or the “Group”)

    Half-year Results

    Manchester, UK – 3 December 2018: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited half-year results for the six months ended 30 September 2018.

    Financial highlights

    •    Revenues increased by 45% to £3.9m (H1 2017-18: £2.7m)
    •    Gross profit up 49% to £2.0m (H1 2017-18: £1.3m)
    •    General administrative expenses down 4% to

    Read More
  • 7 November 2018 - Change of Name to Yourgene Health plc & Change of Website Address +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Change of Name to Yourgene Health plc
    &
    Change of Website Address

    Manchester, UK – 7 November 2018: Premaitha Health plc, the international molecular diagnostics group which commercialises genetic products and services that positively impact human health, is pleased to confirm the renaming of the Group as Yourgene Health plc (“Yourgene Health”).

    Further to the special resolution approved at the Group’s Annual General Meeting on 25 October 2018,

    Read More
  • 12 October 2018 - Trading Update & Notice of Results +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Trading Update & Notice of Results

    Manchester, UK – 12 October 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to provide an update on trading for the six-month period ended 30 September 2018 (“H1”).

    H1 revenues were approximately £3.9 million, an increase of 45 per cent over the corresponding period last year. The Company has made a strong start to the second

    Read More
  • 04 October 2018 - $1 million collaboration agreement +

    Premaitha Health PLC
    (“Premaitha,” the “Company” or the “Group”)

    $1 million collaboration agreement
    Partnership to provide genetic testing based on next generation sequencing for oncology

    Manchester, UK – 4 October 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces a new partnership agreement between the Group’s Yourgene Bioscience division (“Yourgene”) and a leading clinical research organisation in Taiwan (the “Partner”), to deliver next generation sequencing (“NGS”) testing in oncology.

    Under the terms of

    Read More
  • 28 September 2018 - Proposed fundraise to raise approximately £2.5 million +

    THIS ANNOUNCEMENT, INCLUDING THE APPENDIX AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
Pregnant lady sitting at table with Laptop

Investor Relations
Ben Simons / Fiona Henson / Antonia Pollock
Vigo Communications
Sackville House
40 Piccadilly
London W1J 0DR
yourgene@vigocomms.com
T : +44 (0) 20 7390 0230

Two business people looking at computer screen